p53基因与肝癌的研究进展

潘小平; 党彤

p53基因与肝癌的研究进展

潘小平,
党彤

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3292
- HTML全文浏览量: 5
- PDF下载量: 1740
- 被引次数: 0
出版历程
- 出版日期: 2008-04-20

摘要

HTML全文

参考文献(28)

[1]Parkin M, Bray F, Ferlay J, et al.Global Cancer Statistics2002[J].CA Cancer J Clin, 2005, 55 (2) ∶74-108.

[2]Lipinsiki KS, Jieha AH, Krausz E, et al.Tumour-specific thera-peutic adenovirus vectors:repression of transgene expenssion inhealthy cells by endogenous p53[J].Gene Ther, 2001, 8 (4) ∶274-81.

[3]Staib F, Hussain SP, Hofseth LJ, et al.TP53 and liver carcinogene-sis[J].Hum Mutat, 2003, 21 (3) ∶201-216.

[4]Chang SC, Lin JK, Lin TC, et al.Genetic alteration of p53, but notoverexpression of intratumoral p53 protein, or serump53 antibody isa prognostic factor in sporadic colorectal adenocarcinoma[J].Int JOncol, 2005, 26 (1) ∶65-75.

[5]Bergqvist M, Brattstrom D, Larsson A, et al.The role of circulatinganti-p53 antibodies in patients with advanced non-small cell lungcancer and their correlation to clinical parameters and survival[J].BMC Cancer, 2004, 14 (4) ∶66.

[6]卢勤, 滕皋军.p53基因治疗肿瘤的研究进展[J].中华放射学杂志, 2000, 34 (10) ∶659-661.

[7]龚玲, 景钊, 邹长林.乙肝相关性肝癌组织中p27、p53及增殖细胞核抗原的表达[J].中国基层医药, 2007, 14 (1) ∶96-97.

[8]任勇, 陈寿松, 李擒龙, 等.肝细胞肝癌VEGF与p53的表达及其意义[J].华南国防医学杂志, 2006, 20 (6) ∶25-26.

[9]喻宏, 钟仁华, 黄振林.P53、AR、ER在原发性肝癌、癌旁组织中的表达及意义[J].国际医药卫生导报, 2006, 12 (24) ∶12-14.

[10]张志培, 程庆书, 黄立军, 等.HCV C蛋白、p53、Mdm2、p14和p21在原发性肝癌中的表达及相关性[J].现代肿瘤医学, 2006, 14 (10) ∶1252-1255.

[11]官泳松, 刘源, 贺庆, 等.P53抗体与原发性肝癌临床特征的关系[J].世界华人消化杂志, 2007, 15 (3) ∶246-253.

[12]Watanabe J, Nishiyama H, Okubo K, et al.Clinical evaluation ofp53 mutations in urothelial carcinoma by IHC and FASAY[J].U-rology, 2004, 63 (5) ∶989-993.

[13]陈可和, 冯国生, 丁志敏, 等.寡核苷酸芯片技术检测中国肝细胞癌p53基因点突变[J].内科, 2006, 1 (1) ∶12-14.

[14]吴小末, 朱江燕, 王均永, 等.FASAY技术在肝癌p53基因功能突变检测中的应用[J].复旦学报 (自然科学版) , 2006, 45 (6) ∶804-810.

[15]Kashyap R, Jain A, Nalesnik M, et al.Clinical significance of ele-vated alpha-fetoprotein in adults and children[J].Dig Dis Sci, 2001, 46 (8) ∶1709-1713.

[16]Volpert OV, Dameron KM, Bouck N.Sequential development of anangiogenic phenotype by human fibroblasts progressing to tumorige-nicity[J].Oncogene, 1997, 14 (12) ∶1495-1502.

[17]Saffroy R, Lelong JC, Azoulay D, et al.Clinical significance of cir-culating anti-P53 antibodies in European patients with hepatocel-lular carcinoma[J].Br J Cancer, 1999, 79 (3-4) ∶604-610.

[18]Nasif WA, Lotfy M, E1-Sayed IH, et al.Implications of CEAand P53 overexpression in the poor prognosis of colorectalcancer[J].Med Oncol, 2006, 23 (2) ∶237-244.

[19]Shiota G, Kishimoto Y, Suyama A, et al.Prognostic significance ofserum anti-P53 antibody in patients with hepatocellularcarcinoma[J].J Hepatol, 1997, 27 (4) ∶661-668.

[20]Reiser M, Neumann I, Schmiegel W, et al.Induction of cell prolif-eration arrest and apoptosis in hepatoma cells through adenoviral-mediated transfer of p53 gene[J].J Hepatol, 2000, 32 (5) ∶771-782.

[21]Lee TK, Han JS, Fan ST, et al.Gene delivery using a receptor-mediated gene transfar system targeted to hepatocellular carcinomacells[J].Int J Cancer, 2001 (3) , 93∶393.

[22]郭英, 曾益新, 王坤, 等.腺病毒介导的p53抑制肝癌生长的实验研究[J].中华肝脏病杂志, 2001, 9 (S1) ∶43-45.

[23]施明, 王福生, 刘明旭, 等.重组腺病毒介导的人野生型p53、GM-CSF和B7-1基因在肝癌细胞中的表达[J].肿瘤防治研究, 2002, 29 (2) ∶123-125.

[24]朱光宇, 卢勤, 滕皋军.经导管动脉注入脂质体介导的p53基因治疗肝癌的实验研究[J].介入放射学杂志, 2007, 16 (2) ∶109-114.

[25]卢勤, 牛焕章, 朱光宇, 等.经导管动脉输送转铁蛋白增强p53基因转染效率的研究[J].介入放射学杂志, 2007, 16 (2) ∶99-103.

[26]Kuo PL, Chiang L G, Lin CC.Resverarol-induced apoptosis is-mediated by p53-dependent pathway inHepG2 cells[J].Life Sci, 2002, 72 (1) ∶23-34.

[27]丁忠阳, 蔡兵, 穆会君, 等.PTD-p53融合蛋白的表达、纯化及其对肝癌细胞的转导活性[J].东南大学学报 (医学版) , 2007, 26 (3) ∶194-197.

[28]穆红, 王玉亮, 刘蓉.野生型p53基因在人肝癌细胞的表达及诱导其凋亡[J].细胞与分子免疫学杂志, 2006, 22 (6) ∶758-759.

施引文献

资源附件(0)

访问统计